The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

The UK Spirits Alliance said a British tradition of handing brands down through the generations could soon be a thing of the ...

Welcome to the Money blog, Sky News' personal finance and consumer hub. Today: five ways taxes could go up later this year, ...

US President Donald Trump said he plans to start sending letters informing trading partners of their tariff rates.

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

Sharing contact information is a big part of doing business, but the way it’s shared is changing. Paper business cards, once used at every meeting and event, no longer match how most professionals now ...

Welcome to the Money blog, Sky News' personal finance and consumer hub. Today: we sample 13 decaf teas in Our Verdict - and ...

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with ...

-- AstraZeneca is in talks with Summit Therapeutics for a deal in which it could pay as much as $15 billion over time to license a lung-cancer drug, Bloomberg reported Thursday, citing people familiar ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as ...

The yields on UK ten year bonds rose sharply on Wednesday as Keir Starmer failed to guarantee the job of chancellor Rachel ...